Andrew D Goodman

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi request reprint Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions
    Andrew D Goodman
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Infect Dis 187:1365-76. 2003
  2. pmc Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy)
    Andrew D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Neurotherapeutics 10:106-10. 2013
  3. doi request reprint A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
    Andrew D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Ann Neurol 68:494-502. 2010
  4. doi request reprint Dalfampridine in multiple sclerosis
    A D Goodman
    Department of Neurology, University of Rochester, Medical Center, Rochester, New York 14642, USA
    Drugs Today (Barc) 46:635-9. 2010
  5. pmc GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study
    A D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Neurology 72:806-12. 2009
  6. doi request reprint Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
  7. doi request reprint Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
    Andrew D Goodman
    University of Rochester, Rochester, NY, USA
    Lancet 373:732-8. 2009
  8. doi request reprint A randomized trial of memantine as treatment for spasticity in multiple sclerosis
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 16:248-51. 2010
  9. doi request reprint Symptomatic management in multiple sclerosis
    Lawrence M Samkoff
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Neurol Clin 29:449-63. 2011
  10. ncbi request reprint Cognitive fatigue during a test requiring sustained attention: a pilot study
    Steven R Schwid
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 9:503-8. 2003

Detail Information

Publications22

  1. ncbi request reprint Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions
    Andrew D Goodman
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Infect Dis 187:1365-76. 2003
    ....
  2. pmc Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy)
    Andrew D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Neurotherapeutics 10:106-10. 2013
    ..The exact mechanism of action is uncertain, as is the reason for response variability. The medication serves as proof-of-concept that targeting axonal transmission can improve disability in multiple sclerosis...
  3. doi request reprint A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
    Andrew D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Ann Neurol 68:494-502. 2010
    ..The current study was designed to confirm efficacy and further define safety and pharmacodynamics...
  4. doi request reprint Dalfampridine in multiple sclerosis
    A D Goodman
    Department of Neurology, University of Rochester, Medical Center, Rochester, New York 14642, USA
    Drugs Today (Barc) 46:635-9. 2010
    ..The safety profile of dalfampridine is also reviewed, with a focus on the risk for epileptic seizures as an adverse effect...
  5. pmc GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study
    A D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Neurology 72:806-12. 2009
    ..The primary outcome assessed whether this combination would increase the rate of development of new active lesions on cranial MRI scans vs GA alone...
  6. doi request reprint Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
    ..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...
  7. doi request reprint Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
    Andrew D Goodman
    University of Rochester, Rochester, NY, USA
    Lancet 373:732-8. 2009
    ..This phase III study assessed efficacy and safety of oral, sustained-release fampridine in people with ambulatory deficits due to multiple sclerosis...
  8. doi request reprint A randomized trial of memantine as treatment for spasticity in multiple sclerosis
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 16:248-51. 2010
    ..The primary outcome measure for efficacy was the change in Ashworth Spasticity Scale Score. Although well tolerated, memantine treatment did not demonstrate efficacy in treatment of spasticity in this 12-week small exploratory study...
  9. doi request reprint Symptomatic management in multiple sclerosis
    Lawrence M Samkoff
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Neurol Clin 29:449-63. 2011
    ..This article reviews strategies of symptom management in patients with MS...
  10. ncbi request reprint Cognitive fatigue during a test requiring sustained attention: a pilot study
    Steven R Schwid
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 9:503-8. 2003
    ..Motor fatigue can be objectively measured as the decline in strength occurring during sustained contractions. Analogous declines in cognitive performance occur during tasks requiring sustained attention...
  11. ncbi request reprint Neuropsychologic status in multiple sclerosis after treatment with glatiramer
    A Weinstein
    Department of Neurology, University of Rochester Medical Center, NY 14642, USA
    Arch Neurol 56:319-24. 1999
    ..Glatiramer acetate (Copaxone) therapy reduces clinical disease activity in relapsing-remitting multiple sclerosis (MS)...
  12. ncbi request reprint Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study
    A D Goodman
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA rmc rochester edu
    Mult Scler 13:357-68. 2007
    ..To determine the safety of sustained-release 4-aminopyridine in subjects with mutiple sclerosis (MS) and to examine dose-related efficacy up to 40 mg twice daily...
  13. ncbi request reprint Quantitative functional measures in MS: what is a reliable change?
    S R Schwid
    Department of Neurology, University of Rochester Medical Center, NY, USA
    Neurology 58:1294-6. 2002
    ..Therefore, a 20% change on these tests can be considered to be the threshold that reliably indicates a true change in function for an individual...
  14. doi request reprint Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium
    Ilya Kister
    Multiple Sclerosis Care Center, Department of Neurology, New York University School of Medicine, NYU Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003 3804, USA
    Mult Scler 17:725-33. 2011
    ..Although the natural history of multiple sclerosis has been charted extensively, it is still not known whether the trajectory of disability accumulation has changed in the era of disease-modifying therapies (DMTs)...
  15. doi request reprint Broadening the spectrum of controls for skin biopsy in painful neuropathies
    David N Herrmann
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Muscle Nerve 42:436-8. 2010
    ..Distal-leg ENFD/morphology in MS DLLBP patients did not differ significantly from that of healthy controls. This study extends the range of ENFD controls and further supports use of ENFD assessment in SFSN...
  16. doi request reprint Rapid disease course in African Americans with multiple sclerosis
    I Kister
    Department of Neurology, NYU School of Medicine, Multiple Sclerosis Care Center, New York, NY 10003 3804, USA
    Neurology 75:217-23. 2010
    ..MSSS is a frequency-rank algorithm relating MS disability to disease duration in a large, untreated reference population. Design/..
  17. doi request reprint Assessment of JC virus DNA in blood and urine from natalizumab-treated patients
    Richard A Rudick
    Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Ann Neurol 68:304-10. 2010
    ..Analyses were conducted to determine the clinical utility of measuring JC virus (JCV) DNA in blood or urine of natalizumab-treated multiple sclerosis (MS) patients to predict the risk of progressive multifocal leukoencephalopathy (PML)...
  18. doi request reprint Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Mult Scler 14:425-7. 2008
    ....
  19. ncbi request reprint Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial
    Steven R Schwid
    University of Rochester, Department of Neurology, Rochester, NY 14642, USA
    J Neurol Sci 255:57-63. 2007
    ....
  20. ncbi request reprint Fatigue in multiple sclerosis: current understanding and future directions
    Steven R Schwid
    Department of Neurology, University of Rochester Medical Center, NY, USA
    J Rehabil Res Dev 39:211-24. 2002
    ..Dividing fatigue into these components can provide objective assessments that are less likely to be confounded by other symptoms of MS, such as weakness, spasticity, cognitive impairment, and depressed mood...
  21. ncbi request reprint Benefit of interferon beta-1a on MSFC progression in secondary progressive MS
    J A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 59:679-87. 2002
    ..Studies of other IFNbeta preparations in secondary progressive MS (SPMS) yielded conflicting results. This study was undertaken to determine whether IFNbeta-1a slowed disease progression in SP-MS...
  22. ncbi request reprint Infections and MS: clinical trials move to center stage
    Andrew D Goodman
    Neurology 58:7-8. 2002